Statistical review of animal trials-A guideline

被引:3
|
作者
Piper, Sophie K. [1 ,2 ,3 ,4 ,5 ]
Zocholl, Dario [1 ,2 ,3 ,5 ]
Toelch, Ulf [6 ]
Roehle, Robert [1 ,2 ,3 ,5 ,7 ]
Stroux, Andrea [1 ,2 ,3 ,5 ]
Hoessler, Johanna [8 ]
Zinke, Anne [8 ]
Konietschke, Frank [1 ,2 ,3 ,5 ]
机构
[1] Charite Univ Med Berlin, Charitepl 1, D-10117 Berlin, Germany
[2] Free Univ Berlin, Charitepl 1, D-10117 Berlin, Germany
[3] Humboldt Univ, Inst Biometry & Clin Epidemiol, Charitepl 1, D-10117 Berlin, Germany
[4] Humboldt Univ, Inst Med Informat, Berlin, Germany
[5] Charite Univ Med Berlin, Berlin Inst Hlth, Berlin, Germany
[6] Charite Univ Med Berlin, Berlin Inst Hlth, QUEST Ctr Responsible Res, Berlin, Germany
[7] Humboldt Univ, Clin Trial Off, Berlin, Germany
[8] Landesamt Gesundheit & Soziales, Referat Gesundheitlichen Verbraucherschutz, Berlin, Germany
关键词
animal experiment; Animal Welfare Act committee; ethics approval; preclinical research; statistical planning; SIZE;
D O I
10.1002/bimj.202200061
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Any experiment involving living organisms requires justification of the need and moral defensibleness of the study. Statistical planning, design, and sample size calculation of the experiment are no less important review criteria than general medical and ethical points to consider. Errors made in the statistical planning and data evaluation phase can have severe consequences on both results and conclusions. They might proliferate and thus impact future trials-an unintended. outcome of fundamental research with profound ethical consequences. Unified statistical standards are currently missing for animal review boards in Germany. In order to accompany, we developed a biometric form to be filled and handed in with the proposal at the concerned local authority on animal welfare. It addresses relevant points to consider for biostatistical planning of animal experiments and can help both the applicants and the reviewers in overseeing the entire experiment(s) planned. Furthermore, the form might also aid in meeting the current standards set by the 3+3R's principle of animal experimentation: Replacement, Reduction, Refinement as well as Robustness, Registration, and Reporting. The form has already been in use by the concerned local authority of animal welfare in Berlin, Germany. In addition, we provide reference to our user guide giving more detailed explanation and examples for each section of the biometric form. Unifying the set of biostatistical aspects will help both the applicants and the reviewers to equal standards and increase quality of preclinical research projects, also for translational, multicenter, or international studies.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Interpreting the results of noninferiority trials-a review
    Cuzick, Jack
    Sasieni, Peter
    [J]. BRITISH JOURNAL OF CANCER, 2022, 127 (10) : 1755 - 1759
  • [2] Immunotherapies and immunomodulatory approaches in clinical trials-a mini review
    Iqbal Yatoo, Mohd.
    Hamid, Zeenat
    Rather, Izhar
    Nazir, Qurat Ul Ain
    Bhat, Riyaz Ahmed
    Ul Haq, Abrar
    Magray, Suhail Nabi
    Haq, Zulfqar
    Sah, Ranjit
    Tiwari, Ruchi
    Natesan, SenthilKumar
    Bilal, Muhammad
    Harapan, Harapan
    Dhama, Kuldeep
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (07) : 1897 - 1909
  • [3] Traditional plants with antioxidant properties in clinical trials-A systematic review
    Marmitt, Diorge Jonatas
    Bitencourt, Shanna
    da Silva, Gustavo Rodrigo
    Rempel, Claudete
    Goettert, Marcia Ines
    [J]. PHYTOTHERAPY RESEARCH, 2021, 35 (10) : 5647 - 5667
  • [4] Promoting inclusion in clinical trials-a rapid review of the literature and recommendations for action
    Bodicoat, Danielle H.
    Routen, Ash C.
    Willis, Andrew
    Ekezie, Winifred
    Gillies, Clare
    Lawson, Claire
    Yates, Thomas
    Zaccardi, Francesco
    Davies, Melanie J.
    Khunti, Kamlesh
    [J]. TRIALS, 2021, 22 (01)
  • [5] Safety reporting in developing country vaccine clinical trials-A systematic review
    Muehlhans, Susann
    Richard, Georgina
    Ali, Mohammad
    Codarini, Gabriela
    Elemuwa, Chris
    Khamesipour, Ali
    Maurer, Wolfgang
    Mworozi, Edison
    Kochhar, Sonali
    Rundblad, Gabriella
    Vuitton, Dominique
    Rath, Barbara
    [J]. VACCINE, 2012, 30 (22) : 3255 - 3265
  • [6] IPEG guideline on statistical design and analysis for pharmacodynamic trials
    Ferber, G
    Abt, K
    Fichte, K
    Luthringer, R
    [J]. NEUROPSYCHOBIOLOGY, 1999, 39 (02) : 92 - 100
  • [7] Potential of Chlorogenic Acid in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Animal Studies and Clinical Trials-A Narrative Review
    Ziolkiewicz, Agnieszka
    Nizinski, Przemyslaw
    Soja, Jakub
    Oniszczuk, Tomasz
    Combrzynski, Maciej
    Kondracka, Adrianna
    Oniszczuk, Anna
    [J]. METABOLITES, 2024, 14 (06)
  • [8] In reply to the letter to the editor by Jackson and Yeo entitled Cross-over trials-a commentaryCross-over trials-a commentary
    T. J. M. Cleophas
    [J]. European Journal of Clinical Pharmacology, 1997, 52 (2) : 157 - 158
  • [9] The reporting of adverse events following spinal manipulation in randomized clinical trials-a systematic review
    Gorrell, Lindsay M.
    Engel, Roger M.
    Brown, Benjamin
    Lystad, Reidar P.
    [J]. SPINE JOURNAL, 2016, 16 (09): : 1143 - 1151
  • [10] Reporting of PPI and the MCID in phase III/IV randomised controlled trials-a systematic review
    Brennan, Joseph
    Poon, Michael T. C.
    Christopher, Edward
    Fulton, Olivia
    Porteous, Carol
    Brennan, Paul M.
    [J]. TRIALS, 2023, 24 (01)